AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.116 - EXPEDITED PROCEDURE

Page 7

Serial Number: 09/512,926 Filing Date: February 25, 2000

Tille: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIALLY-COMPROMISED VASCULAR SMOOTH MUSCLE

CLEAN VERSION OF PENDING CLAIMS

- 1. [Once Amended] A method to normalize the contractile response of an endothelially-compromised vascular smooth muscle cell to a vasoconstrictor agonist in a patient in need of such normalization, comprising administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof.
- 6. A method of claim 23, wherein the wherein the compound administered is 1-p-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, or a pharmaceutically acceptable salt thereof.
- 7. [Previously Once Amended] A method of claim 23, wherein said endothelium damage is the result of diabetes.
- 8. [Previously Once Amended] A method of claim 23, wherein said endothelium damage is the result of a surgical procedure.
- 9. [Previously Once Amended] A method of claim 23, wherein said endothelium damage is the result or cause of hypertension.
- 10. [Previously Once Amended] A method of claim 23, wherein said endothelium damage is the result or cause of coronary artery disease.
- 11. [Previously Once Amended] A method of claim 23, which further comprises administering a pharmaceutically-effective compound selected from the group consisting of: an anti-diabetes agent; an anti-hypertension agent; an anti-coronary artery disease agent; and an anti-restensis agent.

AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.116 - EXPEDITED PROCEDURE

Page 8 Dkt: 875.039US1

Serial Number: 09/512,926

Filing Date: February 25, 2000

Tide: METHODS TO REDUCE THE SENSITIVITY OF ENDOTIFICIALLY-COMPROMISED VASCULAR SMOOTH MUSCLE

23. [Once Amended] A method of claim 1, wherein the CLC3 blocker is a compound of Formula I

$$\mathsf{R}^{4}\mathsf{R}^{5}\mathsf{N}(\mathsf{CH}_{2})_{\mathsf{n}}\mathsf{O} - \mathsf{C} - \mathsf{C}$$

wherein

either R⁴ is H or a lower alkyl radical and R⁵ is a lower alkyl radical, or R⁴ and R⁵ are joined together with the adjacent nitrogen atom to form a heterocyclic radical;

R⁶ is H or a lower alkyl radical;

R⁷ is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical;

R⁸ is H or OH; and

n is 2;

or a pharmaceutically acceptable salt thereof.